AC
LUCD icon

AlphaCore Capital’s Lucid Diagnostics LUCD Stock Holding History

AlphaCore Capital’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9K Buy
10,175
+175
+2% +$189 ﹤0.01% 1395
2026
Q1 		$11.5K Buy
+10,000
New +$12.7K ﹤0.01% 1106

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AlphaCore Capital's LUCD Position: Q2 2026 in Review

AlphaCore Capital increased its Lucid Diagnostics (LUCD) stake by 1.8% in Q2 2026, buying an estimated $189 and bringing the position to 10,175 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1395.

AlphaCore Capital first reported a position in LUCD in Q1 2026 and has held it in 2 quarters since. The position peaked at $11.5K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • AlphaCore Capital held 10,175 shares of Lucid Diagnostics worth $10.9K as of Q2 2026.
  • AlphaCore Capital bought 175 Lucid Diagnostics shares in Q2 2026, an estimated $189.
  • Lucid Diagnostics made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1395 holding.
  • AlphaCore Capital first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • AlphaCore Capital's Lucid Diagnostics position peaked at $11.5K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.